Mitral Valve Surgery Linked to Lower Rates of Adverse Outcomes in AFMR
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- For patients with atrial functional mitral regurgitation (AFMR), mitral valve (MV) surgery is associated with lower rates of adverse clinical outcomes, according to a study published online Aug. 15 in JAMA Network Open.
Nobuyuki Kagiyama, M.D., Ph.D., from Juntendo University Graduate School of Medicine in Tokyo, and colleagues examined the prevalence, clinical characteristics, and outcomes of MV surgery in AFMR in a retrospective cohort study conducted across 26 Japanese centers.
Overall, 8,867 of the 177,235 patients who underwent echocardiography had moderate or severe MR. Within this group, 11.4 percent were diagnosed with AFMR (80.1 percent had atrial fibrillation). One hundred thirteen of these patients underwent MV surgery, and 81.4 percent received concurrent tricuspid valve surgery. The researchers found that compared with patients who remained under medical therapy, those who underwent surgery were younger, but they had more severe MR (57.5 versus 9.4 percent), a larger mean left atrial volume index (152.5 versus 87.7 mL/m2), and a higher prevalence of heart failure (New York Heart Association class III or IV: 26.5 versus 9.3 percent). Overall, 28.4 percent of patients experienced the primary outcome of heart failure hospitalization and all-cause mortality during a median follow-up of 1,050 days. Only the surgical group had a decrease in natriuretic peptide levels at follow-up and a significantly lower rate of the primary outcome (three-year event rates, 18.3 versus 33.3 percent) despite a more severe disease status.
"Future clinical trials are warranted to investigate the causal relationship between MV surgery and clinical outcomes in patients with severe AFMR," the authors write.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Urinary Metal Levels Tied to Increased Risk for Later Heart Failure
THURSDAY, July 3, 2025 -- There are consistent associations between elevated urinary metal levels and increased heart failure risk over time across geographically diverse cohorts...
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
Quality Improvement Initiative Ups Adherence to Medical Therapy for Heart Failure
MONDAY, June 23, 2025 -- For patients with heart failure, hospital participation in the IMPLEMENT-HF initiative improves adherence to quadruple medication therapy (QMT), defined...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.